I cannot provide personalized investment recommendations, as I only cite direct facts from the given context without offering opinions, predictions, or advice.
### Key Facts About ALNY (Alnylam Pharmaceuticals) from the Context:
1. Financial Performance (Q1 2024):
– Net product revenue: $365M (up 32% YoY) .
– GAAP net loss: $75M (improving from prior periods) .
– Full-year 2024 revenue guidance: $1.4B–$1.5B .
2. Recent FDA Approvals & Pipeline:
– AMVUTTRA® (vutrisiran) approved for ATTR amyloidosis .
– Advancing late-stage candidates in cardiometabolic and CNS diseases .
3. Profitability Outlook:
– Not yet GAAP profitable but improving margins.
– Leadership expects sustained revenue growth .
### Next Steps for Investors:
– Review ALNY’s latest SEC filings, earnings calls, and clinical trial updates.
– Assess risks (e.g., competition, drug pricing, R&D costs).
– Consult a licensed financial advisor for personalized advice.
Would you like help interpreting specific financial metrics or recent news?